- Home
- PHVS vs CMPR Comparison
PHVS vs CMPR Comparison
Compare PHVS & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CMPR
- Stock Information
- Founded
- PHVS 2015
- CMPR 1994
- Country
- PHVS Switzerland
- CMPR Ireland
- Employees
- PHVS N/A
- CMPR N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CMPR Publishing
- Sector
- PHVS Health Care
- CMPR Consumer Discretionary
- Exchange
- PHVS Nasdaq
- CMPR Nasdaq
- Market Cap
- PHVS 1.3B
- CMPR 1.5B
- IPO Year
- PHVS 2021
- CMPR N/A
- Fundamental
- Price
- PHVS $21.65
- CMPR $63.12
- Analyst Decision
- PHVS Buy
- CMPR Strong Buy
- Analyst Count
- PHVS 6
- CMPR 2
- Target Price
- PHVS $36.67
- CMPR $72.00
- AVG Volume (30 Days)
- PHVS 118.6K
- CMPR 210.1K
- Earning Date
- PHVS 08-12-2025
- CMPR 10-29-2025
- Dividend Yield
- PHVS N/A
- CMPR N/A
- EPS Growth
- PHVS N/A
- CMPR N/A
- EPS
- PHVS N/A
- CMPR 0.58
- Revenue
- PHVS N/A
- CMPR $3,403,079,000.00
- Revenue This Year
- PHVS N/A
- CMPR $7.23
- Revenue Next Year
- PHVS N/A
- CMPR $3.64
- P/E Ratio
- PHVS N/A
- CMPR $108.82
- Revenue Growth
- PHVS N/A
- CMPR 3.38
- 52 Week Low
- PHVS $11.51
- CMPR $35.21
- 52 Week High
- PHVS $26.33
- CMPR $102.22
- Technical
- Relative Strength Index (RSI)
- PHVS 47.92
- CMPR 68.75
- Support Level
- PHVS $21.56
- CMPR $61.72
- Resistance Level
- PHVS $24.52
- CMPR $64.37
- Average True Range (ATR)
- PHVS 1.32
- CMPR 2.22
- MACD
- PHVS -0.07
- CMPR 0.04
- Stochastic Oscillator
- PHVS 28.04
- CMPR 87.49
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.